



WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/439, 31/5513, 31/498, A61P 35/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/24395</b> <b>(43) International Publication Date:</b> 4 May 2000 (04.05.00)
<b>(21) International Application Number:</b> PCT/EP99/08004 <b>(22) International Filing Date:</b> 22 October 1999 (22.10.99)  <b>(30) Priority Data:</b> 98250380.7                      28 October 1998 (28.10.98)                      EP  <b>(71)(72) Applicant and Inventor:</b> IKONOMIDOU, Hrisanthi [DE/DE]; Joersstrasse 16, D-13505 Berlin (DE).	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER  <b>(57) Abstract</b>  New use of glutamate antagonists (NMDA, AMPA and kainate receptor antagonists) and their physiologically compatible salts for the preparation of drugs for treatment of cancer is described. New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## DESCRIPTION

**TITLE:** New Use of Glutamate Antagonists for the Treatment of Cancer

**TECHNICAL FIELD:** Pharmaceutical compositions and their uses

### BACKGROUND ART

Glutamate is a major neurotransmitter but possesses also a wide metabolic function in the body. It is released from approximately 40% of synaptic terminals and mediates many physiological functions by activation of different receptor types (Watkins and Evans (1981) Excitatory amino acid transmitters, *Annu. Rev. Pharmacol.*, 21: 165-189; Gasic and Hollmann (1992) Molecular neurobiology of glutamate receptors, *Annu. Rev. Physiol.*, 54: 507-536). Two main categories of glutamate receptors have been identified, ionotropic and metabotropic (Bettler and Mulle, (1995) Neurotransmitter Receptors II, AMPA and Kainate Receptors, *Neuropharmacology*, 34: 123-139; Pin and Duvoisin (1995) Neurotransmitter receptors I, The Metabotropic Glutamate Receptors: Structure and Functions, *Neuropharmacology*, 34: 1-26; Mori and Mishina (1995) Neurotransmitter Receptors VIII, Structure and Function of the NMDA Receptor Channel, *Neuropharmacology*, 34: 1219-1237). Ionotropic glutamate receptors can be subdivided into N-methyl-D-aspartate (NMDA),  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA), and kainate receptors. Metabotropic glutamate receptors can be subdivided into three classes, mGluRI, mGluRII and mGluRIII (Pin and Duvoisin (1995) Neurotransmitter receptors I, The Metabotropic Glutamate Receptors: Structure and Functions, *Neuropharmacology*, 34: 1-26). Five receptor subunits form the functional NMDA receptor which is modulated by glycine and polyamines and blocked by  $Mg^{2+}$ . Activation of NMDA receptors leads to influx of  $Na^{+}$ - and  $K^{+}$ - ions into the cell as well as  $Ca^{2+}$ -ions, either through the receptor channel itself or through voltage dependent  $Ca^{2+}$ -channels (Bettler and Mulle, (1995) Neurotransmitter Receptors II, AMPA and Kainate Receptors, *Neuropharmacology*, 34: 123-139; Mori and Mishina (1995) Neurotransmitter Receptors VIII, Structure and Function of the NMDA Receptor Channel, *Neuropharmacology*, 34: 1219-1237). Four different subunits, named GluR1-GluR4, form the AMPA receptor channel. AMPA receptors are highly permeable to  $Na^{+}$ - and  $K^{+}$ - ions. AMPA

receptor assemblies lacking the GluR2 subunit are also permeable to  $\text{Ca}^{2+}$ -ions (Hollmann M, Heinemann S (1994): Cloned glutamate receptors, *Annu. Rev. Neurosci.*, 17: 31-108).

Kainate receptors are built from five subunits, GluR5-7 as well as KA1 and KA2. Kainate receptor associated ion channels are permeable to  $\text{Na}^{+}$ - and  $\text{K}^{+}$ -ions as well as  $\text{Ca}^{2+}$ .  $\text{Ca}^{2+}$ -permeability of kainate receptor associated ion channels is dependent on the presence of the GluR6 subunit within the receptor complex (Hollmann M, Heinemann S (1994): Cloned glutamate receptors, *Annu. Rev. Neurosci.*, 17: 31-108). There is considerable experimental and clinical evidence indicating that glutamate is involved in the pathogenesis of neuronal degeneration in the context of hypoxia/ischemia and trauma of the central nervous system, seizures and hypoglycemia. In addition, glutamate is thought to be involved in the pathogenesis of chronic neurodegenerative disorders, such as amyotrophic lateral sclerosis, Huntington's, Alzheimer's and Parkinson's disease. Functional glutamate receptors have been also identified in lung, muscle, pancreas and bone (Mason DJ, Suva LJ, Genever PG, Patton AJ, Steuckle S, Hillam RA, Skerry TM (1997) Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? *Bone* 20: 199-205; Patton AJ, Genever PG, Birch MA, Suva LJ, Skerry TM (1998) Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone, *Bone* 22: 645-649). However, no link has been established so far between glutamate receptor stimulation and tumor growth.

Many forms of cancer have been described affecting every form of tissue known in man. Of the described forms of human cancer, none is curable in 100% of the affected patients. Treatment modes include surgical removal, chemotherapy with cytostatic agents alone or in combination with hormone receptor modulators and/or steroids and/or interferons, and radiation (Hill R (1992): Cellular basis for radiotherapy, in *The Basic Science of Oncology*, McGraw-Hill, pp. 259-275).

**I. The term inhibitor of the interaction of glutamate with the AMPA receptor complex applies to:**

1. all agents that bind to the AMPA receptor and prevent or reduce the binding of glutamate to the AMPA binding site in a competitive- or non-competitive manner. These are antagonists of the binding of glutamate to the AMPA receptor;
2. all agents that do not bind to the AMPA receptor binding site but bind or interact with AMPA receptor modulatory sites and thus prevent glutamate from triggering the signal that would occur when glutamate binds to the AMPA binding site;
3. all agents that interact directly with the AMPA-ion channel, i.e. AMPA receptor channel blockers. These agents reduce permeability of the ion channels associated with the AMPA receptor to ions (preferably  $\text{Na}^+$ ,  $\text{K}^+$  and/or  $\text{Ca}^{2+}$ );
4. all agents that decrease the release of glutamate from nerve endings or other tissues and thus prevent glutamate from binding to the AMPA binding sites and from triggering the signal that would occur as a result of binding of glutamate to AMPA binding site;
5. all agents that decrease synthesis of glutamate and thus prevent glutamate from binding to its binding sites;
6. all agents that increase the metabolism of glutamate and therefore prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to its binding sites;
7. all agents that increase the uptake of glutamate and thus decrease the binding of glutamate to AMPA binding site;
8. all agents that interfere with glutamate transporter systems and decrease the concentration of glutamate in synaptic cleft and thus prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to its binding sites;

9. all agents that interact with glutamate and prevent its binding to the AMPA receptor. Such compounds include i.e. glutamate partial agonists or molecules binding to glutamate;
10. antibodies to AMPA receptor subunits, or to the AMPA receptor, or to glutamate decreasing the binding of glutamate to AMPA binding site.

**II. The term inhibitor of the interaction of glutamate with the KA receptor complex applies to:**

1. all agents that bind to the KA receptor and prevent or reduce the binding of glutamate to the KA binding site in a competitive- or non-competitive manner. These are antagonists of the binding of glutamate to the KA receptor;
2. all agents that do not bind to the KA receptor binding site but bind or interact with KA receptor modulatory sites and thus prevent glutamate from triggering the signal that would occur when glutamate binds to the KA binding site;
3. all agents that interact directly with the KA-ion channel, i.e. KA receptor channel blockers. These agents reduce permeability of the ion channels associated with the KA receptor to ions (preferably  $\text{Na}^+$ ,  $\text{K}^+$  and/or  $\text{Ca}^{2+}$ ).
4. all agents that decrease the release of glutamate from nerve endings or other tissues and thus prevent glutamate from binding to the KA binding sites and from triggering the signal that would occur as a result of binding of glutamate to KA binding site;
5. all agents that decrease synthesis of glutamate and thus prevent glutamate from binding to its binding sites;
6. all agents that increase the metabolism of glutamate and therefore prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to its binding sites;

7. all agents that increase the uptake of glutamate and thus decrease the binding of glutamate to KA binding site;
8. all agents that interfere with glutamate transporter systems and decrease the concentration of glutamate in synaptic cleft and thus prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to its binding sites;
9. all agents that interact with glutamate and prevent its binding to the KA receptor. Such compounds include e.g. glutamate partial agonists or molecules binding to glutamate;
10. antibodies to KA receptor subunits, or to the KA receptor, or to glutamate decreasing the binding of glutamate to KA binding site.

**III. The term inhibitor of the interaction of glutamate with the NMDA/glycine/polyamine receptor complex applies to:**

1. all agents that bind to the NMDA receptor or NMDA ion channel associated glycine or polyamine binding site and prevent or reduce the binding of glutamate to the NMDA binding site in a competitive- or non-competitive manner. These are antagonists of the interaction of glutamate with the NMDA receptor;
2. all agents that do not bind to the NMDA receptor binding site but bind or interact with NMDA receptor modulatory sites and thus prevent glutamate from triggering the signal that would occur when glutamate binds to the NMDA binding site;
3. all agents that interact directly with the NMDA-ion channel, i.e. NMDA receptor channel blockers. These agents reduce permeability of the ion channels associated with the NMDA receptor to ions (preferably  $\text{Na}^+$ ,  $\text{K}^+$  and  $\text{Ca}^{2+}$ ).

4. all agents that decrease the release of glutamate from nerve endings or other tissues and thus prevent glutamate from binding to the NMDA binding sites and from triggering the signal that would occur as a result of binding of glutamate to NMDA binding site;
5. all agents that decrease synthesis of glutamate and thus prevent glutamate from binding to NMDA and NMDA channel associated binding sites;
6. all agents that increase the metabolism of glutamate and therefore prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to NMDA and NMDA channel sites;
7. all agents that increase the uptake of glutamate and thus decrease the binding of glutamate to NMDA binding site;
8. all agents that interfere with glutamate transporter systems and decrease the concentration of glutamate in synaptic cleft and thus prevent glutamate from triggering the signal that would occur as a result of binding of glutamate to NMDA binding sites;
9. all agents that interact with glutamate and prevent its binding to the NMDA receptor. Such compounds include e.g. glutamate partial agonists or molecules binding to glutamate;
10. antibodies to NMDA receptor subunits, or to the NMDA receptor, or to glutamate decreasing the binding of glutamate to NMDA binding site.

Various glutamate antagonists and receptor channel blockers that are within the scope of the present invention will now be described in greater detail:

**A. AMPA receptor antagonists -**



AMPA receptor antagonists refer to compounds that bind to AMPA receptors in a competitive manner or interact with AMPA receptor associated sites and block AMPA mediated signal in a non-competitive manner.

Such antagonists include L-glutamate derivatives, amino alkanoic acid derivatives,  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionate derivatives, acetyl-aminophenyl-dihydro-methyl-dioxolo-benzodiazepine, acid amide derivatives, amino-phenyl-acetic acid, 2,3-benzodiazepine-4-one, alkoxy-phenyl-benzodiazepine, amino- or desamino-2,3-benzodiazepine, benzothiadiazine,  $\beta$ -carboline-3-carboxylic acid, fused cycloalkylquinoxalinediones, decahydroisoquinoline, 4-hydroxypyrrolone, 4-hydroxy-pyrrolo-pyridazinone, imidazopyrazinone, imidazolo-quinoxalinone, indeno-pyrazine-carboxylic acid, indeno-pyrazinone, indoloneoxime, indolo-pyrazinone, isatine, isatinoxime, oxadiazole, phenyl-azolophthalazine, phenylpyridazino-indole-1,4-dione, quinoline, quinolinone, quinoxaline, quinoxalinedione, quinazolinone, quinolone, nitroquinolone, and sulphamate derivatives.

#### **B. AMPA receptor channel blockers -**

AMPA receptor channel blockers refer to compounds that reduce the permeability of channels associated with the AMPA receptor to cations (preferably to  $\text{Na}^+$ ,  $\text{K}^+$  and/or  $\text{Ca}^{2+}$  ions). AMPA receptor channel blockers can therefore be used to prevent a signal being transmitted due to ionic flux that would otherwise occur when glutamate binds to the AMPA receptor.

AMPA receptor channel blockers include e.g. fluorowillardiine, Joro spider toxin, NSTX spider toxin, argiotoxin.

#### **C. KA receptor antagonists -**

KA receptor antagonists refer to compounds that bind to KA receptors in a competitive manner or interact with KA receptor associated sites and block KA mediated signal in a non-competitive manner.

Such antagonists include L-glutamate derivatives, kainic acid derivatives, acid amide derivatives, aminoalkanoic acid derivatives, aminophenyl(alkyl)acetic acid derivatives, fused cycloalkylquinoxalinediones, quinoxalinedione, imidazolo-quinoxalinone, isatine, phenyl-azolophthalazine, pyridothiazines, 4-phosphonoalkyl-quinolinone, quinolinone, quinazoline, quinazolinedione, quinoxalinedione and sulphamate derivatives.

#### **D. KA receptor channel blockers -**

KA receptor channel blockers refer to compounds that reduce the permeability of channels associated with the KA receptor to cations (preferably to Na<sup>+</sup>, K<sup>+</sup> and/or Ca<sup>2+</sup> ions). KA receptor channel blockers can therefore be used to prevent a signal being transmitted due to ionic flux that would otherwise occur when glutamate binds to the KA receptor.

KA receptor channel blockers include i.e. Joro spider toxin, NSTX spider toxin and argitoxin 636.

#### **E. NMDA/glycine/polyamine receptor antagonists -**

NMDA/glycine receptor antagonists refer to compounds that bind to NMDA receptors in a competitive manner or interact with NMDA receptor associated sites and block NMDA mediated signal in a non-competitive manner.

Such antagonists include L-glutamate derivatives, tetrahydroquinolines, imidazoloquinoxalinones, isatines, fused cycloalkylquinoxalinediones, quinoxalines, spermine, 4-hydroxy-3-nitro-1,2-dihydroquinolon-2-one derivatives, indole derivatives, benzo-thiadiazine dioxide derivatives, indeno(1,2-b)pyrazin-3-ones or corresponding 2,3-diones, quinoline derivatives, ethyl(phenyl-carbamoyl)-ethenyl)dichloroindole carboxylates, thienopyrazine 2,3-dione derivatives, 2-(2,3-dicarboxycyclopropyl) glycine, 2-amino-3-substituted phenyl propionic acid derivatives, 1-carboxyalkylquinoxaline-2,3(1H,4H)dione derivatives, thienyl-glycine derivatives, benzo-fused azacyclic compounds, tricyclic quinoxaline-diene derivatives, 3-hydroxy anthranilic acid and salts, decahydroisoquinolines, tri- or terta-substituted guanidine

derivatives, D- or L-tryptophan derivatives, tetrazolyl(alkyl)-cyclohexyl-aminoacid derivatives, octahydrophenanthrene derivatives, benzomorphan, piperazinyl or piperidinyl-alkyl substituted isoxazole derivatives, decahydroisoquinoline-3-carboxylic ester or its amide preparation, compounds based on Conantokin-G peptide, 3-heterocyclyl-alkyl-benzopyran-2-one derivatives, phosphono-alkyl imidazo-pyrimidine carboxylic acid derivatives, amantadine, memantine, rimantidine, histogranin and analogues, nitrobenzoic acid derivatives, e.g 4-((2-methoxycarbonyl-4-nitrophenyl)methyl)piperazine carboxylic acid, diamine derivatives with selective sigma receptor affinity, remacemide (2-amino-N-(1,2-diphenyl-1-methylethyl)acetamide), phosphono-alkylidene- or phosphono-alkoxy-imino-piperidine acid, benzothiadiazine carboxylic acid derivatives, dihydro-benzothiadiazine dioxide carboxylic acid derivatives, 4-hydroxy 2(H) pyrrolone derivatives, quinoxaline derivatives, tetrahydro-imidazo(1,2-a)pyrimidines or their salts, 4-hydroxy-pyrrolo(1,2-b)pyridazin-2(1H)-one derivatives, nitroquinolone derivatives, 3-aryl-substituted 2(1H)quinolone, 2(1H)-quinolone, phosphonic acid quinoline-2-carboxylic acid derivatives, benzimidazole(s) carrying 2 acidic groups, N,N'-disubstituted guanidine derivatives, tricyclic quinoxalinediones, 2-(2,3-dicarboxycyclopropyl) glycine, isatine derivatives, 3-amino-indolyl-derivatives, 2-phenyl-1,3-propanediol dicarbamate (felbamate), benzomorphan derivatives, dihydrothienopyridine derivatives, (aminophenyl)-heteroaryl ethylamine, pyridazinedione derivatives, a 2H-1-benzopyran-2-one compound, a 4-sulphonylamino-quinoline derivative, R(plus)-3-amino-1-hydroxy-pyrrolidine-2-one, 2-carboxy indole, substituted. imino-methano dibenzo(A,D)cycloheptene derivatives, indole-hydrazone, piperazine derivatives, 4,6-disubstituted tryptophan and kynurenine derivatives, fluorenamine, diketo-pyridopyrazine derivatives or its salts, 2-amino-3,4-dioxo-1-cyclobutene derivatives, 2-acyl-amido derivatives of 3,4-dihydro-3-oxo-quinoxaline, benzimidazole phosphono-aminoacid derivatives, quinoxaline phosphono-aminoacid derivatives, piperazine, piperidine or pyrrolidone derivatives, its salts and isomeric forms including stereoisomers, 4-hydroxy-2(1H)-quinolinone derivatives, its salts and prodrugs, fused pyrazine derivatives, 2-phenyl or 2-thienyl-(2)-piperidine derivatives, 3-amido or 3-sulphamido-indolyl derivatives, 3-aryl-4-hydroxy-2-(1H)-quinolone derivatives, 2-heterocyclyl-2-hydroxy-ethylamine derivatives, 1-aryl-2-aminomethyl pyrrolidine, its optical isomers and acid-addn. salts, 4,6-dihalo indole-2-carboxylic acid derivatives, cyclic amino-hydroxamate derivatives, tetracyclic amine derivatives, 2,4-dioxo-

1,2,3,4-tetrahydroquinoline derivatives, 2,4-dioxo-1,2,3,4-tetrahydroquinoline derivatives, 3-phosphonopiperidine and p-pyrrolidine derivatives, benzothieno(2,3-B)-pyrazine-2,3-(1H,4H)-dione, spiro dibenzosuberane derivatives, benzomorphan derivatives, preparation of 3,4-disubstituted 2-isoxazoline(s) and isoxazoles(s), 3-indolyl thio-acetate derivatives, arginine-derived nitric oxide biosynthesis inhibitors, dicyclic amine derivatives, spiroisindole derivatives, imidazo(1,2-A)-pyridinylalkyl, 1,2,3,4-tetrahydro-9H-pyridoindole or benzothiophene derivatives, indole-2,3-dione-3-oxime derivatives, 1-aryl-2-(aminomethyl)cyclopropanecarboxamide derivatives, 4-phosphono-2-amino-alkenoic acid derivatives, naphthopyran derivatives, beta-ketone, beta oxime or beta hydrazine phosphonate, topa quinone aminoacid, kynurenic acid, quinoline- or thienopyridine-carboxylic acid derivatives, 10,5-(imino-methano)-10,11-dihydro-5H-dibenzo(A,D)cycloheptene or its derivatives, bicyclic amino-hydroxamate derivatives, indole-2-carboxylic acid derivatives, substituted adamantane derivatives, benzobicycloalkane derivatives, 2,4-disubstituted-1,2,3,4-tetrahydro-quinoline derivatives, dihydro-alkyl-substituted-(immunomethano)-5H-dibenzo-cycloheptene, aryl-cyclohexylamine, N-substituted benzobicycloalkane amine, isoquinoline phosphonates, N,N'-disubstituted-guanidine, phosphonopropenyl piperidine carboxylic acid, (2R,3S,4S)-alpha-carboxy-cyclo-propyl-glycine, pyrrolidine derivatives, dihydroxy-fused heterocyclyl quinoxaline derivatives, hydrogenated derivatives of MK 801 and analogues, 5-substituted 10,11-dihydro 5H-dibenzo(a,d)cycloheptene-5,10-imine, 11-exo-hydroxy MK 801 preparations, tetra hydro-isoquinoline or 2-benzazepine derivatives, N-3-phenyl-propionyl-substituted spermine or related polyamine derivatives, 4a-amino-fluorene or its heterocyclic analogues, cyclooctane-imine derivatives, R-3-amino-1-hydroxy pyrrolidin-2-one or methionine hydroxamate, 10,11-dihydro-5H-dibenzo-cyclohepten-5,10-imine, polyhydro-10,11-dihydro-5H-benzo(a,d)cyclohepten-5,10 imine derivatives, 4-oxo-1,4-dihydroquinoline with 2-acidic groups, heterocyclyl-alkene-phosphonic acid, phosphono group-containing pyridine 2-carboxylic acid, alpha-amino-alpha-(3-alkylphenyl)alkyl ethanoic acid, its esters or amides, 10,11-dihydro-5H-dibenzo-A,D-cyclohepten-5,10-imine, phosphorus containing unsaturated amino acids or their salts, 5 substituted-1,11-dihydro-5H-dibenzo-cyclohepten-5,10-imine or analogues, heterocyclic phosphonic acid derivatives or their salts, substituted 4-(amino-carbonyl-amino)quinoline derivatives, tricyclic quinoxaline derivatives, butyryl-tyrosine spermine or one of its analogues, tri- or tetra-substituted guanidine, quinoxalinyllalkyl-

aminoalkane phosphonic acid derivatives, 2-(aminophenyl)-3-(2-carboxy-indol-3-yl)-propenoic acid derivatives, 6-piperidinypropionyl-2(3H)-benzoxazolone derivatives, 6-(3-[4-(4-fluorobenzyl)piperidin-1-yl]propionyl)-3H-benzoxazol-2-one or its salts, imidazo(1,2-a)pyridine, tetrahydroquinoline derivatives or their salts, 2-methyl-5,8-substituted 2,3,4,5-tetra- or 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole, 3-aminoindolyl, 6-pyrrolyl-quinoxaline-2,3-dione derivatives, imidazolyl-(mercaptoalkyl)-quinoxaline-dione, 3-amidoindolyl derivatives, heterocyclyl-imidazolo-quinoxalinone, naphthyl-substituted alpha-amino acid derivatives, 5-hetero-aryl-2,3-quinoxaline-dione derivatives, quinoxaline derivatives, 5H,10H-imidazo indeno 4-pyrazinone derivatives, hydroxy-(aryl-substituted phenyl)-quinolone, imidazo indolo pyrazinone derivatives, ((phenyl-amino)-(m)ethyl)-pyridine derivatives, tetrahydro-isoquinoline derivatives, 4-substituted piperidine analogues, 2-substituted piperidine derivatives, tri- or tetra-substituted guanidine derivatives, 3-hydroxy-4-imidazolidinone, 3-aminoquinoxalin-2-one derivatives, 1-amino-1-cyclobutanecarboxylic acid, thiamorphinan derivatives, pyrido[4,3-b]indole derivatives, 4-phenyl carbamoyl methylene tetrahydro quinoline-2-carboxylic acid or derivatives thereof, (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman-4,7-diol, indeno-pyrazin-4-one, 2,3-dioxo-1,2,4,5-tetrahydro-quinoxaliny derivatives, 4,5-bridged quinoxalinedione or quinolone, (1S,2S)-1-(4-hydroxyphenyl)2-(4-hydroxy 4-phenyl piperidin-1-yl) 1-propanol methane sulphonate trihydrate, 4-sulphanimide-quinoline derivatives, methanobenzocyclodecen-13-amine, quinoxaliny-(alkane, alkene, or alkyne)-phosphonic acid derivatives and esters, diarylalkylamine related to spider and wasp venom toxins, piperazine R-alpha-carboxylic acid derivatives, imidazo-indeno-pyrazin-4-one derivatives, pyridazino-quinoline derivatives, 1-substituted or 1,3-di-substituted 1,3-diaryl-guanidine, aza-cycloalkyl-fused quinoxaline-dione, 3-substituted 2-carboxy-indole derivatives or intermediates, (2R)-N-trityl-4-oxo-5-(dimethyl phosphono)-nor-valinate ester, kynurenic acid derivatives, indole carboxylic acid derivatives, 6-(tetrazolyl or isoxazolyl)-decahydroisoquinoline-3-carboxylic acid derivatives, phenyl- or pyridinyl-thieno-pyridinone derivatives, fused cycloalkyl-quinoxaline-dione derivatives, pyridazino-quinoline derivatives, 1-alpha-amino-3-biphenyl-propanoic acid derivatives, 3-(Indol-3-yl)propenoic acid derivatives, spiro-heterocycle-imidazo-indeno-pyrazine-4-one derivatives, 2-heterocyclyl-3-indolylpropenoic acid derivatives, piperidinoalkyl heterocyclic ketone, pyrrolyl-tetrahydro-benzoquinoxaline-dione derivatives, 7-imidazolyl or

dialkylamino, tetrahydroquinoxaline dione, dibenzocycloheptene, quinoxaline derivatives, aryl-thio-quinoxaline derivatives, heterocyclic substituted imidazo-quinoxaline derivatives, 1,4-dihydro-quinoxaline-2,3-dione derivatives, oxa- or thia-aliphatically bridged quinoxaline derivatives, aza-aliphatically bridged quinoxaline-2,3-dione, 3-amido- or 3-sulphamido-indole, 3,5-disubstituted phenyl-naphthalene derivatives, imidazo (1,2-a)indeno (1,2-e) pyrazine-2-carboxylic acid derivatives, 3-phenyl-fused ring pyridine-dione derivatives, 2-phenyl-pyridazino-indole-dione derivatives, 4,6-disubstituted kynurenine, phosphono derivatives of imidazo(1,2-a)pyrimidine-2-carboxamide, tetrahydro-quinoxaline-dione derivatives with N-(alkyl)carbonyl-amino- or ureido group, tryptophan derivatives, hetero-aliphatic or hetero-araliphatic substituted quinolone derivatives, imidazo-pyridine dicarboxylic acid derivatives, compositions containing pyrazolo-quinoline derivatives, ethanodihydrobenzoquinolizinium salt, oxopyridinylquinoxaline derivatives, indeno-triazolo-pyrazin-4-one derivatives, imidazo-indeno-pyrazinone derivatives, imidazo-indeno-pyrazin-4-one derivatives, imidazo(1,2-a)pyrazine-4-one derivatives, 5H-indeno-pyrazine-2,3-dione derivatives, phenyl-aminoalkyl-cyclopropane N,N-diethyl carboxamide, dexanabinol derivatives, substituted chroman derivatives, sulphonamide quinazoline-2,4-dione, 6- and 8-aza-, and 6,8-diaza-1,4-dihydro-quinoxaline-2,3-dione derivatives, substituted quinoline derivatives, tetrazolylalkyl cyclohexyl aminoalkanoic acid, tricyclic indole 2-carboxylic acid derivatives, 6-substituted-7H-imidazo-8-pyrazinone derivatives, tricyclic pyridazinopyridine derivatives, N-substituted heterocyclidenemethyl-indole carboxylic acid derivatives, 3-aza-8-substituted-bicyclo(3.3.0)octane-2-carboxylic acid derivatives, ethano-heterocyclo-isoquinolinium, phenyl alkanolamine derivatives, dihydrobenzothiadiazinedioxide carboxylic acid derivatives, methyl-butenylmethyl(hydroxy-propyl)carbazoledione, imidazo pyrazinone derivatives, imidazo-(1,2-a)pyrazine-4-one, benzazepine-dione derivatives, disulfiram, 3-(indol-3-yl)-propenoic acid derivatives, 1,2,3,4-tetrahydro-quinoline-2,3,4-trione-3 or 4-oxime, 2-amino-2-phenyl(alkyl)-acetic acid derivatives, 6-halo-tryptophan or a 4-halo-kynurenine, 6-tetrazolyl or isoxazolyl-decahydro-isoquinoline-3-carboxylic acid derivatives, or imidazolylbenzene or salts thereof.

#### **F. NMDA receptor channel blockers -**

NMDA receptor channel blockers refer to compounds that reduce the permeability of channels associated with the NMDA receptor to cations (preferably to Na<sup>+</sup>, K<sup>+</sup> and Ca<sup>2+</sup> ions). NMDA receptor channel blockers can therefore be used to prevent a signal being transmitted due to ionic flux that would otherwise occur when glutamate binds to the NMDA receptor.

NMDA receptor channel blockers include i.e. magnesium, dizocilpine, phencyclidine, ketamine, memantine, tiletamine, budipine, flupirtine, 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP), (+)-(3S,4S)-7-hydroxy-delta6-tetrahydrocannabinol-1,1-dimethylheptyl (HU211).

#### **G. Glutamate release inhibitors -**

Such agents decrease the release of glutamate from nerve endings and prevent glutamate from binding to either AMPA, kainate, or NMDA binding sites and from triggering the signal that would occur as a result of binding of glutamate to these binding sites.

Glutamate release inhibitors include e.g. riluzole, lamotrigine, diphenylhydantoin, tetrodotoxin, agatoxin-glutamate-release-inhibitor (AG-GI), [5-(2,3,5-trichlorophenyl)]-2,4-diaminopyrimidine (BW1003C87), (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) and 4-amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)pyrimidine (BW619C89).

#### **H. Glycine release inhibitors -**

Such agents decrease the release of glycine from nerve endings and prevent glycine from binding to glycine B binding sites and from triggering the signal that would occur as a result of binding of glutamate to NMDA binding site.

#### **I. Glutamate synthesis inhibitors and drugs interfering with glutamate metabolism -**

Such compounds block synthesis of glutamate or increase metabolism of glutamate preventing activation of either AMPA, kainate or NMDA binding sites.

Compounds interacting with glutamate synthesis or metabolism and preventing activation of either AMPA, kainate or NMDA receptors include e.g. gabapentin, L-canaline, phenylsuccinate, spermidine, putrescine, gentamicin, orthovanadate, vanadyl sulphate, vanadyl acetylacetonate, methionine sulfoximine, chloroquine, amodiaquine, quinacrine, chinidine, chinine,  $\alpha$ -monofluoromethylputrescine and (R,R)-delta-methyl- $\alpha$ -acetylenic-putrescine.

**J. Compounds accelerating glutamate uptake -**

Such agents decrease synaptic concentration of glutamate by activating uptake mechanisms for glutamate preventing activation of either AMPA, kainate or NMDA receptors.

Compounds accelerating glutamate uptake mechanisms include e.g.  $\gamma$ -glutamyl-transpeptidase.

**K. Agents that interact with glutamate and prevent its binding to its receptors -**

Such agents include i.e. glutamate partial agonists which activate glutamate receptors by themselves but are less active than glutamate at these receptors and therefore decrease activation of these receptors by glutamate at physiological and excessively high concentrations or molecules binding to glutamate which change conformational state of glutamate and therefore decrease its binding capability to its receptors.

Glutamate partial agonists are e.g. D-serine, D-cycloserine,  $\gamma$ -L-glutamylglutamate, N-phthalamoyl-L-glutaminic acid, (R,S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid,  $\alpha$ -N-acetylasparylglutamate, 1-aminocyclopropanecarboxylic acid, aminocyclobutane carboxylic acid, (+,R)-3-amino-1-hydroxy-2-pyrrolidine (HA966) and D,L-threo-3-hydroxyaspartate.

Furthermore such agents include soluble forms of NMDA, kainate or AMPA receptors or parts thereof. These soluble forms can be used to circulate and to bind to glutamate and therefore decrease its binding capability to the receptors. Membrane bound forms of the glutamate



receptors may also be incorporated into liposomes, circulate and bind to glutamate so as to prevent it binding to its receptors.

**L. Agents that interact with glutamate transporter systems -**

Such agents accelerate glutamate transporter function and decrease glutamate concentration at its receptors preventing activation of either AMPA, kainate or NMDA receptors.

Such agents include e.g. 12-O-tetradecanoylphorbol-13-acetate, phorbol-12-myristate 13-acetate.

**M. Antibodies interacting with AMPA receptors or with glutamate -**

The AMPA, kainate or NMDA receptors or a part or parts of them, or glutamate can be used for raising antibodies that bind thereto. Preferred antibodies bind specifically to either AMPA, kainate or NMDA receptor or a part thereof, or to glutamate. The antibodies may be monoclonal or polyclonal. Polyclonal antibodies can be raised by stimulating their production in a suitable animal host (e.g. a mouse, rat, guinea pig, rabbit, sheep, goat or monkey) when either AMPA, kainate or NMDA receptor, or a part thereof, or glutamate is injected into the animal. If necessary an adjuvant may be administered together with the AMPA, kainate or NMDA receptor, or a part thereof, or with glutamate. In addition to whole antibodies, antagonists of the present invention include derivatives thereof.

## DISCLOSURE OF THE INVENTION

The present inventor has provided evidence that glutamate antagonists suppress tumor growth. This invention represents a major advance in the treatment of cancer.

According to the present invention, glutamate antagonists which block glutamate function at NMDA, AMPA or kainate receptor complexes, when used alone or in combination with cytostatic agents or physical measures, such as irradiation, will result in anticancer activity superior to that achieved with cytostatic agents or physical measures alone.

The present invention will now be described by way of example only, with reference to the accompanying drawings, wherein:

### Examples

The tumor cell lines used in the context of this invention have been obtained from human tumors. Agents active against tumor growth *in vitro* have proved to also be effective anticancer agents *in vivo*.

The surprising observation that glutamate antagonists have antiproliferative actions in tumor cells and that the tumoricidal effect of three different cytostatic agents, cisplatin, vinblastin and thiotepa is significantly enhanced by two different AMPA antagonists, GYKI 52466 and NBQX (2,3-dihydroxy-6-nitro-7-sulfaoylbenzo-(F)-quinoxaline) and the NMDA antagonist MK 801 is described in the following paragraphs.

**Cell lines and culture.** Human neuroblastoma (SKNAS), human rhabdomyosarcoma/medulloblastoma (TE671), human brain astrocytoma (MOGGCCM), human thyroid carcinoma (FTC238), human Caucasian lung carcinoma (A549), human Caucasian colon adenocarcinoma (LS180) and human breast carcinoma (T47D) were obtained from European Collection of Cell Cultures (ECACC), Center for Applied Microbiology & Research, Salisbury, UK.

SKNAS, TE671, T47D, LS180 were grown in 1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM; D 6421, Sigma,  $\text{Ca}^{2+}$ -concentration 1.05mM) and Nutrient Mixture F-12 Ham (Ham's F-12; Sigma) supplemented with 10% Foetal Bovine Serum (FBS) (GIBCO). FTC238 was grown in the same culture medium supplemented with 5% FBS. MOGGCCM and A549 were grown in 2:1 mixture of DMEM (D 6046, Sigma,  $\text{Ca}^{2+}$ -concentration 1.8mM):Ham's F-12 supplemented with 10% FBS. Cultures were kept at 37°C in a 95% air-5%  $\text{CO}_2$  atmosphere. As  $\text{Ca}^{2+}$ -free medium, minimum essential medium M8167 from Sigma was used.

**Assessment of cell viability.** The yellow tetrazolium salt MTT (3-4,5-dimethylthiazol-2- 2,5-diphenyltetrazolium bromid) is metabolized by viable, metabolically active cells to purple formazan crystals. Tumor cells grown in 96 well multiplates were incubated over 4 hrs with MTT solution (Cell proliferation kit I, Boehringer Mannheim, Germany). Formazan crystals were solubilized overnight, according to the manufacturer's instructions, and the product was quantified spectrophotometrically by measuring absorbance at 570nm wave length using a VICTOR Multilabel Counter (Wallach).

**Assessment of tumoricidal effect.** Quantitation of cell death was performed at 24, 48 or 72 hrs after exposure to the agents of interest following staining of the cells with trypan blue. This stain is taken up by necrotic cells. The numbers of necrotic cells/100 counted cells served as quantitative measure for tumoricidal effect (% of tumor cell death). For each agent or combination of agents and each time point 5 wells were analysed. Comparisons between groups was performed by means of Student's t-test.

**Exposure to agents.** Tumor cells were exposed to the following agents and concentrations: MK 801 (10-500 $\mu\text{M}$ ), GYKI 52466 (10 -500  $\mu\text{M}$ ), Cisplatin (10  $\mu\text{M}$ ), Vinblastin (1  $\mu\text{M}$ ), Thiotepea (10  $\mu\text{M}$ ) alone or in combination with MK 801 (10 $\mu\text{M}$ ), GYKI 52466 (10  $\mu\text{M}$ ) or NBQX (10  $\mu\text{M}$ ).

## Results

The NMDA antagonist MK801 and the AMPA antagonists GYKI52466 displayed a significant concentration-dependent antiproliferative effect in different tumor cell lines (Figs. 1 and 2).

In addition, NMDA and AMPA antagonists enhanced tumoricidal effect of cytostatic agents (Fig. 3-5). Each of the cytostatic agents tested produced a significant tumoricidal effect on its own at the concentrations used, which reached a peak for all three agents after 72 hrs exposure time. The NMDA antagonist MK 801 and the AMPA antagonists GYKI 52466 and NBQX significantly ( $P < 0.05-0.001$ ) potentiated tumoricidal effect of cisplatin, vinblastin and thiotepa when used in combination with the cytostatic agents. This potentiation of the tumoricidal effect of the cytostatic agents by the NMDA and the AMPA antagonists was most prominent after an exposure time of 72 hrs for cisplatin and thiotepa and 48 hrs for vinblastin (Figs. 3-5).

#### BRIEF DESCRIPTION OF DRAWINGS

**FIG. 1:** The NMDA antagonist (+)dizocilpine exerts a concentration dependent antiproliferative effect in human tumor cell lines. Cells were exposed to either culture medium alone (control) or dizocilpine (10-500  $\mu$ M) over 96 hrs and viability was measured photometrically by means of the MTT assay. Data represent mean normalized optical densities  $\pm$  SEM of 6-8 measurements and were analyzed by means of linear regression. *Abbreviations.* SKNAS: human neuroblastoma; TE671: human rhabdomyosarcoma/ medulloblastoma; MOGGCCM: human brain astrocytoma; FTC238: human thyroid carcinoma; A 549: human Caucasian lung carcinoma; LS180: human Caucasian colon adenocarcinoma; T47D: human breast carcinoma.

**FIG. 2:** The AMPA antagonist GYKI52466 exerts a concentration dependent antiproliferative effect in human tumor cell lines. Cells were exposed to either culture medium alone (control) or GYKI52466 (10-500  $\mu$ M) over 96 hrs and viability was measured photometrically by means of the MTT assay. Data represent mean normalized optical densities  $\pm$  SEM of 6-8 measurements and were analyzed by means of linear regression. *Abbreviations.* SKNAS: human neuroblastoma; TE671: human rhabdomyosarcoma/ medulloblastoma; MOGGCCM: human brain astrocytoma; FTC238: human thyroid carcinoma; A 549: human Caucasian lung carcinoma; LS180: human Caucasian colon adenocarcinoma; T47D: human breast carcinoma.

**FIG. 3** shows that the the NMDA antagonist MK801 (10 $\mu$ M), and the AMPA receptor antagonists GYKI 52466 (10  $\mu$ M) or NBQX (10  $\mu$ M) significantly increase toxicity of cisplatin

(10  $\mu$ M) against the human neuroblastoma cell line SK-N-AS. Data represent the mean  $\pm$  SEM of necrotic cells visualized by trypan blue staining (n = 5/group). The potentiating effect of all three glutamate receptor antagonists was most prominent after an exposure time of 72 h. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001, Student's t test.

**FIG. 4** shows that MK801 (10  $\mu$ M), GYKI 52466 (10  $\mu$ M) or NBQX (10  $\mu$ M) potentiate toxicity of thiotepa (10  $\mu$ M) against the tumor cell line SK-N-AS. Data represent the mean  $\pm$  SEM of necrotic cells visualized by trypan blue staining (n = 5/group). The potentiating effect of the NMDA- and both AMPA antagonists is most prominent after an exposure time of 72 h. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001, Student's t test.

**FIG. 5** shows that MK 801 (10 $\mu$ M), GYKI 52466 (10  $\mu$ M) or NBQX (10  $\mu$ M) potentiate toxicity of vinblastin (1  $\mu$ M) against the tumor cell line SK-N-AS. Data represent the mean  $\pm$  SEM of necrotic cells visualized by trypan blue staining (n = 5/group). The potentiating effect of the NMDA- and both AMPA antagonists is most prominent after an exposure time of 48 hrs. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001, Student's t test.

#### **BEST MODE FOR CARRYING OUT THE INVENTION**

Use of various tumor cell lines in culture and exposure of the tumor cells over 72-96 hrs either to glutamate antagonists alone or to glutamate antagonists in combination with cytostatic agents is required and should be performed as described in „Disclosure of the Invention“. Quantification of cell death can be performed by means of trypan blue staining and direct counting of the degenerated cells in the microscope. Quantification of metabolically active cells can be performed photometrically by means of the MTT-assay. Culture techniques, trypan blue staining and photometric MTT-measurements are known and established methods which can easily be carried out in every cell culture laboratory.

## INDUSTRIAL APPLICABILITY

### Therapeutic use

Glutamate inhibitors of the present invention may be used in human and veterinary medicine. Treatments may be prophylactic or may be in respect of existing conditions.

The glutamate antagonists may be used in the manufacture of a medicament for treating cancer. The term cancer is used herein to include any disorder that results from abnormal and uncontrolled cell growth with resulting invasion and destruction of neighbouring tissue which can but must not set metastases to distant tissues. The present invention includes within its scope pharmaceutically acceptable compositions useful in treating cancer which comprise a glutamate antagonist of the present invention. The antagonist will usually be provided in combination with a pharmaceutically acceptable carrier. It may be used in any suitable form, provided that it can act in inhibiting the interaction of glutamate with the AMPA, KA or NMDA/glycine/polyamine receptor complex. Pharmaceutically acceptable salts may also be used.

Pharmaceutical compositions within the scope of the present invention may include one or more of the following: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colorants, odourants, salts, buffers, coating agents or antioxidants. They may contain a further therapeutically active agent in addition to a antagonist of the present invention. The further therapeutically active agent may be a cytostatic agent, an immunomodulating agent or physical measures such as irradiation, photomodulation or hyperthermia. The agents of present invention can also be combined with mono- or polyclonal antibodies, antisense therapeutics, cancer vaccines, or gene therapy.

The combination of an antagonist of the present invention and a further therapeutically active agent may be used simultaneously, separately or sequentially to treat cancer. It may provide synergistically effective combination. A pharmaceutical composition within the scope of the present invention may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) routes. Such a composition may be prepared by any method known

in the art of pharmacy, for example by admixing one or more active ingredients with a suitable carrier. Preferably it will be provided in unit dosage form. It will normally be provided in a sealed, sterile container – e.g. in an ampoule, a vial, a bottle, a blister pack, or etc. Different drug delivery systems can be used to administer pharmaceutical compositions of the present invention, depending upon the desired route of administration. Such systems include aerosols, tablets, capsules, lozengers, pastilles, powders, solutions, suspensions, syrups, ointments, pastes, oils, suppositories, enemas, pessaries, tampons, sprays, nebulizers, injectable compositions, etc.

Dosages of the inhibitors of the present invention can vary between wide limits, depending upon the nature of the treatment and the age and condition of the individual to be treated. However, a daily dosage of from 0.01 mg to 1000 mg, preferably of from 0.5-200 mg may be suitable. The dosage may be repeated as often as appropriate. If side-effects develop, the amount and/or frequency of the dosage can be reduced, in accordance with good clinical practice.

#### **Diagnostic Use**

Diagnostic use is possible for testing whether a form of cancer is susceptible to treatment with glutamate antagonists. This testing would involve isolation and culturing of tumor cells and subsequently testing tumoricidal effect of glutamate antagonists alone or in combination with cytostatic agents, or immunomodulating agents, or physical measures such as irradiation, photomodulation, or hyperthermia.

## CLAIMS

1. The use of an inhibitor of the interaction of glutamate with the AMPA receptor complex in the manufacture of a medicament for treating cancer.
2. The use according to claim 1, wherein the type of cancer includes all kinds of cancer.
3. The use according to any preceding claim wherein the inhibitor is an antagonist of the binding of glutamate to the AMPA receptor.
4. The use according to any preceding claim, wherein the inhibitor is an L-glutamate derivative, an  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionate derivative, acid amide derivatives, amino alkanolic acid, amino-phenyl-acetic acid, amino- or desamino- 2,3-benzodiazepine, 2,3-benzodiazepin-4-one, alkoxy-phenyl-benzodiazepine, acetyl-aminophenyl-dihydro-methyl-dioxolo-benzodiazepine, benzothiadiazine, decahydroisoquinoline,  $\beta$ -carboline-3-carboxylic acid, fused cycloalkylquinoxalinedione, 4-hydroxypyrrolone, 4-hydroxy-pyrrolo-pyridazinone, indeno-pyrazine-carboxylic acid, indeno-pyrazinone, indoloneoxime, indolo-pyrazinone, indolo-pyrazinone, imidazo-pyrazinone, imidazolo-quinoxalinone, isatine, isatinoxime, oxadiazole, phenyl-azolophthalazine, phenylpyridazino-indole-1,4-dione, quinoline, quinolone, quinolonone, nitroquinolone, quinoxaline, quinoxalinedione, quinazolinone, 4-hydroxy-pyrrolo-pyridazinone, phenyl-azolophthalazine or sulphamate derivatives.
5. The use according to any of claims 1 to 4, wherein the inhibitor is L-glutamic acid diethylester, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX), 6,7-dinitro-quinoxaline-2,3-dione (DNQX), 6-nitro-7-cyano-quinoxaline-2,3-dione (CNQX), 6-(1-imidazolyl)-7-nitro-quinoxaline-2,3(1H, 4H)-dione (YM90K), [2,3-dioxo-7(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxaliny]-acetic acid monohydrate (YM872), (3RS,4aRS,6RS,8aRS)-6-(2-(1H-tetrazole-5-yl)ethyl)-decahydroiso-quinoline-3-carboxylic acid (LY293558), 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX), 8-methyl-5-(4-(N,N-dimethylsulphamoyl)phenyl)-6,7,8,9-tetra-hydro-1H-pyrrolo[3,2h]-



isoquinoline-2,3-dione-3-O-(3-hydroxybutyric acid-2-yl)oxime (NS 1209), 6,7-dichloro-2-(1H)-quinolinone-3-phosphonate (S 17625-2), [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl]methyl-phosphonate (ZK200775), 1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy-5H-2,3-benzodiazepine (GYKI52466), topiramate and 5-{2-[2-(N,N-dimethylamino)ethyl]oxy-phenyl}-3-phenyl-1,2,4-oxadiazol, 1-(4-aminophenyl)-3-methylcarbamoyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 53655), (-)-1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodiazepine (GYKI53773), dimethyl-{2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-phenoxy]ethyl}-amine hydrochloride (BIIR 561).

6. The use according to any of claims 1 to 2, wherein the inhibitor is an AMPA receptor channel blocker.
7. The use according to claim 6, wherein the AMPA receptor channel blocker is fluorowillardiine, Joro spider toxin, NSTX spider toxin, argiotoxin, or their derivatives.
8. The use of an inhibitor of the interaction of glutamate with the KA receptor complex in the manufacture of a medicament for treating cancer.
9. The use according to claim 8, wherein the type of cancer includes all kinds of cancer.
10. The use according to claim 8 and 9 wherein the inhibitor is an antagonist of the binding of glutamate to the KA receptor.
11. The use according to claims 8 to 10, wherein the inhibitor is an L-glutamate derivative, kainic acid derivative, domoic acid derivative, acid amide derivative, aminoalkanoic acid derivative, aminophenyl(alkyl)acetic acid derivative, isatine, quinoxalinedione, fused cycloalkylquinoxalinedione, imidazolo-quinoxalinone, phenyl-azolophthalazine, pyridothiazines, quinazoline, quinazolinone, 4-phosphonoalkyl-quinolinone, quinoxalinedione, or sulphamate derivative.

12. The use according to any of claims 8 to 11, wherein the inhibitor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX), 6,7-dinitro-quinoxaline-2,3-dione (DNQX), 6-nitro-7-cyano-quinoxaline-2,3-dione (CNQX), 6-(1-imidazolyl)-7-nitro-quinoxaline-2,3-(1H,4H)-dione (YM90K), [2,3-dioxo-7(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxaliny]-acetic acid monohydrate (YM872), (3RS,4aRS,6RS,8aRS)-6-(2-(1H-tetrazole-5-yl)ethyl)-decahydroiso-quinoline-3-carboxylic acid (LY293558), 9-methyl-amino-6-nitro-hexahydro-benzo(F)quinoxalinedione (PNQX), 8-methyl-5-(4-(N,N-dimethylsulphamoyl)phenyl)-6,7,8,9-tetra-hydro-1H-pyrrolo[3,2h]-isoquinoline-2,3-dione-3-O-(3-hydroxybutyric acid-2-yl)oxime (NS 1209), 6,7-dichloro-2-(1H)-quinolinone-3-phosphonate (S17625-2), [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-(trifluoromethyl)quinoxalin-1-yl]methyl-phosphonate (ZK200775), 1-(aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466),  $\gamma$ -D-glutamylaminomethylsulphonate (GAMS),  $\gamma$ -D-glutamylglycine.
13. The use according to any of claims 8 to 9, wherein the inhibitor is an KA receptor channel blocker.
14. The use according to claim 13, wherein the KA receptor channel blocker is fluorowillardiine, Joro spider toxin, NSTX spider toxin, argiotoxin, or their derivatives.
15. The use of an inhibitor of the interaction of glutamate with the NMDA/glycine/polyamine receptor/ion channel complex in the manufacture of a medicament for treating cancer.
16. The use according to claim 1, wherein the type of cancer includes all kinds of cancer.
17. The use according to claims 15 to 16 wherein the inhibitor is an antagonist of the binding of glutamate to the NMDA receptor or NMDA receptor associated binding sites such as e.g. glycine or polyamine binding sites.

18. The use according to claims 15 to 17, wherein the inhibitor is an L-glutamate derivative, a 4-hydroxy-3-nitro-1,2-dihydroquinolon-2-one derivative, an indole derivative, a benzothiadiazine dioxide derivative, an indeno(1,2-b)pyrazin-3-one or corresponding 2,3-dione, a quinoline derivative, an ethyl(phenyl-carbamoyl)-ethenyl)dichloroindole carboxylate, a thienopyrazine 2,3-dione derivative, a 2-(2,3-dicarboxycyclopropyl) glycine, a 2-amino-3-substituted phenyl propionic acid derivative, 1-carboxyalkylquinoxaline-2.3(1H,4H)dione derivative, a thienyl-glycine derivative, an indole derivative, a tricyclic quinoxaline-diene derivative, a 3-hydroxy anthranilic acid, a decahydroisoquinoline, a tri- or terta-substituted guanidine derivative, a D- or L-tryptophan derivative, a tetrazolyl(alkyl)-cyclohexyl-aminoacid derivative, an octahydrophenanthrene derivative, a benzomorphan, a piperazinyl or piperidinyl-alkyl substituted isoxazole derivative, a decahydroisoquinoline-3-carboxylic ester or its preparation, a compounds based on Conantokin-G peptide, a 3-heterocyclyl-alkyl-benzopyran-2-one derivative, a phosphono-alkyl imidazo-pyrimidine carboxylic acid derivative, amantadine, memantine, rimantidine, a histogranin peptide or analogue, a nitrobenzoic acid derivative, e.g 4-((2-methoxycarbonyl-4-nitrophenyl)methyl)piperazine carboxylic acid, a diamine derivative with selective sigma receptor affinity, remacemide (2-amino-N-(1,2-diphenyl-1-methylethyl)acetamide), a phosphono-alkylidene- or phosphono-alkoxy-imino-piperidine acid, a benzothiadiazine carboxylic acid derivative, a dihydro-benzothiadiazine dioxide carboxylic acid derivative, a 4-hydroxy 2(H) pyrrolone derivative, a quinoxaline derivative, a tetrahydro-imidazo (1,2-a) pyrimidines or its salt, a alpha-amino acid, a 4-hydroxy-pyrrolo(1,2-b)pyridazin-2(1H)-one derivative, a nitroquinolone derivative, a 3-aryl-substituted 2(1H)quinolone, a 2(1H)-quinolone, a phosphonic acid quinoline-2-carboxylic acid derivative, its per hydro quinoline derivative, a benzimidazole(s) carrying 2 acidic groups, an N,N'-disubstituted guanidine derivative, a tricyclic quinoxaline dione, a 2-(2,3-dicarboxycyclopropyl) glycine stereoisomer, an isatine derivative, a 3-amino-indolyl-derivative, 2-phenyl-1,3-propanediol dicarbamate (felbamate), a benzomorphan derivative, a dihydrothienopyridine derivative, an enantiomer of (aminophenyl)-heteroaryl ethylamine, a pyridazine-dione derivative, a 2H-1-benzopyran-2-one, a 4-sulphonylamino-quinoline derivative, a R-3-amino-1-hydroxy-pyrrolidine-2-one, a 2-carboxy indole, a substituted imino-methano dibenzo (A,D)cycloheptene derivative, an indole-hydrazone, a piperazine derivative, a 4,6-disubstituted tryptophan and kynurenine derivative, a fluorenamine, a diketo-pyrido pyrazine derivative, a 2-

amino-3,4-dioxo-1-cyclobutene derivative, a 2-acyl-amido derivative of 3,4-dihydro-3-oxo-quinoxaline, a benzimidazole phosphono-aminoacid derivative, a quinoxaline phosphono-aminoacid derivative, a piperazine, piperidine or pyrrolidone derivative, its salts and isomeric forms including stereoisomers, a 4-hydroxy-2(1H)-quinolinone derivative, its salts and prodrugs, a fused pyrazine derivative, a 2-phenyl or 2-thienyl-(2)-piperidine derivative, a 3-amido or 3-sulphamido-indolyl derivative, a 3-aryl-4-hydroxy-2-(1H)-quinolone derivative, a 2-heterocyclyl-2-hydroxy-ethylamine derivative, a 1-aryl-2-aminomethyl pyrrolidine, its optical isomers and acid-addn. salts, a 4,6-dihalo indole-2-carboxylic acid derivative, a cyclic amino-hydroxamate derivative, a tetracyclic amine derivative, a 2,4-dioxo-1,2,3,4-tetrahydroquinoline derivative, a 2,4-dioxo-1,2,3,4-tetrahydroquinoline derivative, a 3-phosphonopiperidine and pyrrolidine derivative, a benzothieno (2,3-B)-pyrazine-2,3-(1H,4H)-dione, a spiro dibenzosuberane derivative, a benzomorphan derivative, a preparation of 3,4-disubstituted 2-isoxazoline(s) and isoxazoles(s), a 3-indolyl thio-acetate derivative, an arginine-derived nitric oxide biosynthesis inhibitor, a dicyclic amine derivative, a spiroisoindole derivative, an imidazo(1,2-A)-pyridinylalkyl, a 1,2,3,4-tetrahydro-9H-pyrido indole or benzothiophene derivative, an indole-2,3-dione-3-oxime derivative, a 1-aryl-2-(aminomethyl)cyclopropanecarboxamide derivative, a 4-phosphono-2-amino-alkenoic acid derivative, a naphthopyran derivative, a beta-ketone, a beta oxime or beta hydrazine phosphonate, a topa quinone aminoacid, kynurenic acid or its derivative, a quinoline- or thienopyridine-carboxylic acid derivative, a 10,5-(imino-methano)-10,11-dihydro-5H-dibenzo(A,D)cycloheptene or a derivative, a bicyclic amino-hydroxamate derivative, an indole-2-carboxylic acid derivative, a substituted adamantane derivative, a benzobicycloalkane derivative, a 2,4-disubstituted-1,2,3,4-tetrahydro-quinoline derivative, a dihydro-alkyl-substituted-(immunomethano)-5H-dibenzo-cycloheptene, an aryl cyclohexylamine, an N-substituted benzobicycloalkane amine, an isoquinoline phosphonate derivative, an N,N'-disubstituted-guanidine, a phosphonopropenyl piperidine carboxylic acid, (2R,3S,4S)-alpha-carboxy-cyclo-propyl-glycine, a pyrrolidine derivative, a dihydroxy-fused heterocyclyl quinoxaline derivative, a hydrogenated derivative of MK 801 and analogues, a 5-substituted 10,11-dihydro 5H-dibenzo (a,d) cycloheptene 5,10-imine, an 11-exo-hydroxy MK 801 preparation including electrochemical cyclisation step to form 5,10-imine bridge in 5-methyl 5-oxyamino 5H-dibenzo (A,D) cycloheptene, a tetra hydro-isoquinoline or 2-

benzazepine derivative, an N-3-phenyl-propionyl-substituted spermine or related polyamine derivative, a 4a-amino-fluorene or its heterocyclic analogue, a cyclooctane-imine derivative, a R-3-amino-1-hydroxy pyrrolidin-2-one or methionine hydroxamate, a 10,11-dihydro-5H-dibenzo-cyclohepten-5,10-imine, a polyhydro-10,11-dihydro-5H-benzo(a,d)cyclohepten-5,10 imine derivative, a 4-oxo-1,4-dihydroquinoline with 2-acidic groups, a heterocyclyl-alkene-phosphonic acid, a phosphono gp-containing pyridine 2-carboxylic acid, an alpha-amino-alpha-(3-alkylphenyl)alkyl ethanoic acid, its esters or amides, a 10,11-dihydro-5H-dibenzo-A,D-cyclohepten-5,10-imine, a phosphorus containing unsaturated amino acid or its salts, a 5 substituted-1,11-dihydro-5H-dibenzo-cyclohepten-5,10-imine, a heterocyclic phosphonic acid derivative, a substituted 4-(amino-carbonyl-amino)quinoline, a tricyclic quinoxaline derivative, a butyryl-tyrosine spermine or its analogues, a tri- or tetra-substituted guanidine, a quinoxalinyllalkyl-aminoalkane phosphonic acid derivative, a 2-(aminophenyl)-3-(2-carboxy-indol-3-yl)-propenoic acid derivative, a 6-piperidinylpropionyl-2(3H)-benzoxazolone derivative, 6-(3-[4-(4-fluorobenzyl)piperidin-1-yl]propionyl)-3H-benzoxazol-2-one, an imidazo(1,2-a)pyridine, a tetrahydroquinoline derivative, a 2-methyl-5,8-substituted 2,3,4,5-tetra- or 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole, a 3-aminoindolyl compound, a 6-pyrrolyl-quinoxaline-2,3-dione derivative, an imidazolyl-(mercaptoalkyl)-quinoxaline-dione, a 3-amidoindolyl derivative, a heterocyclyl-imidazolo-quinoxalinone, a naphthyl-substituted alpha-amino acid, a 5-hetero-aryl-2,3-quinoxaline-dione, a quinoxaline derivative, a 5H,10H-imidazo indeno 4-pyrazinone derivative, a hydroxy-(aryl-substituted phenyl)-quinolone, an imidazo indolo pyrazinone derivative, a ((phenyl-amino)-(m)ethyl)-pyridine derivative, a tetrahydro-isoquinoline derivative, a 4-substituted piperidine, a 2-substituted piperidine derivative, a tri- or tetra-substituted guanidine derivative, a 3-hydroxy-4-imidazolidinone, a 3-aminoquinoxalin-2-one derivative, 1-amino-1-cyclobutanecarboxylic acid, a thiamorphinan derivative, a pyrido[4,3-b]indole derivative, 4-phenyl carbamoyl methylene tetrahydro quinoline-2-carboxylic acid derivatives, (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxy-piperidin-1-yl)-chroman-4,7-diol, a phenol derivative, an indeno-pyrazin-4-one, a 2,3-dioxo-1,2,4,5-tetrahydro-quinoxalinyll derivative, a 4,5-bridged quinoxalinedione or quinolone, (1S,2S)-1-(4-hydroxyphenyl)2-(4-hydroxy 4-phenyl piperidin-1-yl) 1-propanol methane sulphonate trihydrate, a 4-sulphanimide-quinoline derivative, a methanobenzocyclodecen-13-amine, a quinoxalinyll-(alkane,alkene,or alkyne)-phosphonic acid, a diarylalkylamine related to spider

and wasp venom toxins, a piperazine R-alpha-carboxylic acid derivative, an imidazo-indeno-pyrazin-4-one derivative, a pyridazino-quinoline derivative, a 1-substituted or 1,3-disubstituted 1,3-diaryl-guanidine, an aza-cycloalkyl-fused quinoxaline-dione, a 3-substituted 2-carboxy-indole derivative, a (2R)-N-trityl-4-oxo-5-(dimethyl phosphono)-nor-valinate ester, a kynurenic acid derivative, an indole carboxylic acid derivative, a 6-(tetrazolyl or isoxazolyl)-decahydroisoquinoline-3-carboxylic acid derivative, a phenyl- or pyridinyl-thieno-pyridinone derivative, a fused cycloalkyl-quinoxaline-dione derivative, a pyridazino-quinoline derivative, a 1-alpha-amino-3-biphenyl-propanoic acid derivative, a 3-(indol-3-yl)propenoic acid derivative, a spiro-heterocycle-imidazo-indeno-pyrazine-4-one derivative, a 2-heterocyclyl-3-indolylpropenoic acid derivative, a piperidinoalkyl heterocyclic ketone or alcohol, a pyrrolyl-tetrahydro-benzoquinoxaline-dione derivative, a 7-imidazolyl or dialkylaminotetrahydroquinoxaline dione, a dibenzocycloheptene, a quinoxaline derivative, an aryl-thio-quinoxaline derivative, a heterocyclic substituted imidazo-quinoxaline derivative, a 1,4-dihydro-quinoxaline-2,3-dione derivative, an oxa- or thio-aliphatically bridged quinoxaline derivative, an aza-aliphatically bridged quinoxaline-2,3-dione, a 3-amido- or 3-sulphamido-indole, a 3,5-disubstituted phenyl-naphthalene derivative, an imidazo (1,2-a)indeno (1,2-e) pyrazine-2-carboxylic acid derivative, a 3-phenyl-fused ring pyridine-dione derivative, a 2-phenyl-pyridazino-indole-dione derivative, a 4,6-disubstituted kynurenine, a phosphono derivative of imidazo(1,2-a)pyrimidine-2-carboxamide, a tetrahydro-quinoxaline-dione derivative with N-(alkyl)carbonyl-amino- or ureido group, a tryptophan derivative, a hetero-aliphatic or hetero-araliphatic substituted quinolone derivative, an imidazo-pyridine dicarboxylic acid derivative, an ethanodihydrobenzoquinolizinium, an oxopyridinylquinoxaline derivative, an indeno-triazolo-pyrazin-4-one derivative, an imidazo-indeno-pyrazinone derivative, an imidazo-indeno-pyrazin-4-one derivative, an imidazo(1,2-a)pyrazine-4-one derivative, a 5H-indeno-pyrazine-2,3-dione derivative, a phenyl-aminoalkyl-cyclopropane N,N-diethyl carboxamide, a dextranabinol derivative, a substituted chroman derivative, a sulphonamide quinazoline-2,4-dione, a 6- and 8-aza-, and 6,8-diaza-1,4-dihydro-quinoxaline-2,3-dione derivative, a substituted quinoline derivative, a tetrazolylalkyl cyclohexyl aminoalkanoic acid, a tricyclic indole 2-carboxylic acid derivative, a 6-substituted-7H-imidazo-8-pyrazinone derivative, a tricyclic pyridazinopyridine derivative, an N-substituted heterocyclylidenemethyl-indole carboxylic acid derivative, a 3-aza-8-substituted-

bicyclo(3.3.0)octane-2-carboxylic acid derivative, an ethano-heterocyclo-isoquinolinium, a phenyl alkanolamine derivative, a dihydrobenzothiadiazinedioxide carboxylic acid derivative, a methyl-butenylmethyl(hydroxy-propyl)carbazoledione, an imidazo pyrazinone derivative, an imidazo-(1,2-a)pyrazine-4-one, a benzazepine-dione derivative, disulfiram, a 3-(indol-3-yl)-propenoic acid derivative, a 1,2,3,4-tetrahydro-quinoline-2,3,4-trione-3 or 4-oxime, a peptide antagonist at NMDA receptors, a 2-amino-2-phenyl(alkyl)-acetic acid derivative, 6-halo-tryptophan or a 4-halo-kynurenine, a 6-tetrazolyl or isoxazolyl-decahydro-isoquinoline-3-carboxylic acid derivative, or an imidazolylbenzene or salts thereof.

19. The use according to any of claims 15 to 18, wherein the inhibitor is 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonate (CPP), 2-(carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid (D-CPPene), 2-amino-5-pentanoic acid (AP5), 2-amino-7-heptanoic acid (AP7), selfotel (CGS19755), (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP101606), 5-nitro-6,7-dichloro-quinoxalinedione (ACEA1021), pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)-, monosodium salt (ZD9379), 1H-indole-2-carboxylic acid, 4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-, monosodium salt (GV150526), 1-aminocyclopropanecarboxylic acid (ACPC), eliprodil (SL820715), lubeluzole, aminophosphovaleric acid, memantine (1-amino-3,5-dimethyladamantane), 3-(4-chlorophenyl)glutamic acid, (+)-beta-cyclazocine, (-)-beta-cyclazocine, DL-(E)-2-amino-4-methyl-5-phosphono-3-pentanoic acid (CGP 37849), 3-[(RS)-2-carboxypiperazin-4-yl]propyl-1-phosphonic acid, ketamine, phencyclidine, dextrophan, dextromethorphan, N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine hydrochloride (aptiganel, CNS1102), ifenprodil, (+)-alpha-phenyl-2-pyridine-ethanamide (FPL 15896AR), 5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI), bis(3-aminopropyl)nonanediamine (TE393), N-(3-aminopropyl)octanediamine, magnesium salts, 2R,4R,5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphono-heptanoic acid, 3-amino-1-hydroxy-2-pyrrolidinone (HA 966), D-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (CGP 40116), (+/-)(E)-2-amino-4-methyl-5-phosphono-3-pentenoate ethylester (CGP39551), (+)-(3S,4S)-7-hydroxy-delta 6-tetrahydrocannabinol-(1,1)-dimethylheptyl (HU 211), (+)-1-methyl-1-phenyl-1,2,3,4-tetrahydro-isoquinoline hydrochloride (FR115427), (+/-)-6-phosphonomethyl-decahydroisoquinolin-3-carboxylic acid (LY274614), 3-isoquinolinecarboxylic acid, decahydro-6-(1H-tetrazol-5-ylmethyl)-, [3R-

(3 $\alpha$ ,4 $\alpha$ ,6 $\beta$ ,8 $\alpha$ )] (LY 233536), 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoate (NPC 12626), (2R,4R,5S-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 17742), procyclidine, D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 40116), (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine, D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid, D-norvaline-4-oxo-5-phosphono (MDL-100453), cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 39653), conantokin-T, conantokin-G,  $\gamma$ -L-glutamyl-L-aspartate, (+/-)-(2SR,4SR)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid, DL-(E)-2-amino-4-methyl-5-phosphono-3-pentanoic acid (CGP 37849), (+/-)-3-carboxy-5-phosphono-1,2,3,4-tetrahydroisoquinoline (SC 48981), 1,2,3,4-tetrahydro-5-(2-phosphonoethyl)-3-isoquinoline-carboxylic acid, (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606,1), (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol (12a, CP-283,097), ifenprodil derivatives 1-piperidineethanol,4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-[R-(R\*,R\*)] (CP-101,581) and 1-piperidineethanol,4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-(alphaS,betaS) (CP-98,113), (+/-)-(E)-beta-cyclazocine, D- $\alpha$ -aminoadipate (DAA), zinc salts, ibogaine, dextropropoxyphene, [3H]1-[1-(2-thienyl)cyclohexyl]piperidine (TCP), 2-phenyl-1,3-propane-diol dicarbamate (felbamate), kynurenic acid, amantadine, flupirtine (Katadolon), nitrous oxide (laughing gas), 4-{3-[4-(4-fluoro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-hydroxy-propoxy}-benzamide (Ro 8-4304), N1,N4,N8-tri-benzyl-spermidine (TB-3-4), 1(-)-3R,4aS,6R,8aR-6-(phosphonomethyl)-decahydroiso-quinoline-3-carboxylic acid (LY235959), 2H-1,2,4-benzothiadiazine-1-dioxide-3-carboxylic acid (RPR 104632), dizocilpine maleate {(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5, 10-imine maleate} ((+)MK-801), 2R, 4R, 5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid) (NPC 17742), cis-(+/-)-4-[(2H-tetrazol-5-yl)methyl]piperidine-2-carboxylic acid (LY 233053), 2-amino-6-phosphonohexanoic acid, D-2-amino-5-phosphonovaleric acid (5-APV), (+)-2-amino-N-ethyl-alpha-(3-methyl-2-thienyl)benzeneethanamine 2HCl (8319), desipramine, [3H]N-(1-(2-thienyl)-cyclohexyl)-3,4-piperidine (TCP), 4-(phosphonomethyl)-phenylglycine (PD 129635), 3-(phosphonomethyl)phenylalanine (PD 130527), tiletamine, arginine vasopressin, O-phosphohomoserine, D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CAS 137424-81-8), [+/-]-5-aminocarbony-10,11-dihydro-5H-dibenzo[a,d]cycloheptan-5,10-imine (ADCI), 7-



chlorokynurenate, ketoprofen, [(S)-Alpha-phenyl-2-pyridine-ethanamine dihydrochloride] ARL 15896AR, ((3S,4aR, 6R, 8aR)-6-[2-(1 H-tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroiso-quinoline-3 -carboxylic acid) (LY293558).

20. The use according to any of claims 15 to 16, wherein the inhibitor is an NMDA receptor channel blocker.

21. The use according to claim 20, wherein the NMDA receptor channel blocker is dizocilpine (MK801), memantine, budipine, flupirtine, remacemide, phencyclidine, tiletamine, ketamine, carvedilol, aptiganel (CNS1102), remacemide (FPL12924AA), 7-hydroxy- Delta (6)-tetrahydrocannabinol 1,1-dimethylheptyl (Dexanabinol; HU211), 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP), or their derivatives.

22. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is a glutamate release inhibitor.

23. The use according to claim 22, wherein the glutamate release inhibitor is i.e. riluzole, lamotrigine, diphenylhydantoin, tetrodotoxin, agatoxin-glutamate-release-inhibitor (AG-GI), [5-(2,3,5-trichlorophenyl)]-2,4-diamino-pyrimidine (BW1003C87), (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) and 4-amino-2-(4-methyl-1-piperaziny)-5-(2,3,5-trichlorophenyl)pyrimidine (BW619C89) or any other agent that decreases the release of glutamate from nerve endings and prevents glutamate from binding to its binding sites and from triggering the signal that would occur as a result of binding of glutamate to its binding sites.

24. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is a glutamate synthesis inhibitor.

25. The use according to claim 24, wherein the glutamate synthesis inhibitor is gabapentin, L-canaline, phenylsuccinate, spermidine, putrescine, gentamicin, orthovanadate, vanadyl sulphate, vanadyl acetylacetonate, methionine sulfoximine, chloroquine, amodiaquine, quinacrine, chinidine, chinine,  $\alpha$ -monofluoromethylputrescine and (R,R)-delta-methyl- $\alpha$ -

acetylenic-putrescine, or any other agent which interacts with glutamate synthesis or metabolism and prevents activation of its receptors by glutamate.

26. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is an agent accelerating glutamate uptake.

27. The use according to claim 26, wherein the agent accelerating glutamate uptake is  $\gamma$ -glutamyl-transpeptidase, or any other agent which decreases synaptic concentration of glutamate by activating uptake mechanism for glutamate.

28. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is an agent that interacts with glutamate itself and prevents its binding to glutamate receptors.

29. The use according to claim 28, wherein the agent that interacts with glutamate is D-serine, D-cycloserine,  $\gamma$ -L-glutamylglutamate, N-phthalamoyl-L-glutaminic acid, (R,S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid,  $\alpha$ -N-acetylaspartylglutamate, 1-aminocyclopropanecarboxylic acid, aminocyclobutane carboxylic acid, (+,R)-3-amino-1-hydroxy-2-pyrrolidine (HA966) and D,L-threo-3-hydroxyaspartate, or any other agent which changes conformational state of glutamate and therefore decreases its binding to receptors. Furthermore such agents include soluble forms of AMPA, kainate or NMDA receptors or parts thereof which can be used to circulate and to bind to glutamate and therefore decrease its binding capability to the receptors.

30. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is a glutamate transporter activator that decreases the concentration of glutamate and prevents its binding to the AMPA, kainate or NMDA receptors.

31. The use according to claim 30, wherein the agent that blocks glutamate transporter is 12-O-tetradecanoylphorbol-13-acetate and phorbol-12-myristate 13-acetate, or any other agent which accelerates the function of glutamate transporters.

32. The use according to any of claims 1 to 2, 8 to 9, and 15 to 16 wherein the inhibitor is an antibody interacting with AMPA, kainate, or NMDA receptors of parts of it or with glutamate and prevents binding of glutamate to its receptors.

33. The use according to claim 32, wherein a preferred antibody which binds specifically to the AMPA, kainate or NMDA receptor or a part thereof, or to glutamate is monoclonal or polyclonal or derivative thereof.

34. The use according to any preceding claim wherein the inhibitor is combined with one or more of:

a cytostatic agent (such as alkylating agents e.g. nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, busulfan, nitrosoureas, BCNU, CCNU, methyl-CCNU; such as antimetabolites e.g. antifolates, pyrimidine and purine analogs including e.g. methotrexate, 5-fluorouracil, azathioprine, cytosine arabinoside, 6-thioguanine, 6-mercaptopurine; such as natural products based anticancer drugs including e.g. doxorubicin, daunorubicin, daunomycin, actinomycin D, bleomycin, mitoxantrone, neocarzinostatin, procarbazine, mitomycin C, vinblastine, vincristine, etoposide; such as intercalating drugs e.g. cisplatin, carboplatin; and other anticancer drugs such as e.g. dacarbazine);

an immunomodulating agent (e.g. corticosteroids as e.g. prednisone and methylprednisolone; interferons such as interferon- $\alpha$  (IFN- $\alpha$ ), IFN- $\beta$ , IFN- $\gamma$ , and other potential modulators such as e.g. interleukins (IL-1 - IL7));

and with physical measures such as irradiation, or hyperthermia. The agents of present invention can also be combined with mono- or polyclonal antibodies, antisense therapeutics, cancer vaccines, and gene therapy.

35. A method of screening for an agent useful in treating cancer, determining whether or not said agent is an inhibitor of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complex on tumor cells.

36. A pharmaceutical composition comprising an inhibitor as described in any of claims 1 to 34 and a pharmaceutically acceptable carrier.

37. A combined preparation of an inhibitor as described in any of claims 1 to 34 and one or more of:

a cytostatic agent (such as alkylating agents e.g. nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, busulfan, nitrosoureas, BCNU, CCNU, methyl-CCNU; such as antimetabolites e.g. antifolates, pyrimidine and purine analogs including e.g. methotrexate, 5-fluorouracil, azathioprine, cytosine arabinoside, 6-thioguanine, 6-mercaptopurine; such as natural products based anticancer drugs including e.g. doxorubicin, daunorubicin, daunomycin, actinomycin D, bleomycin, mitoxantrone, neocarzinostatin, procarbazine, mitomycin C, vinblastine, vincristine, etoposide; such as intercalating drugs e.g. cisplatin, carboplatin; and other anticancer drugs such as e.g. dacarbazine),

an immunomodulating agent (e.g. corticosteroids as e.g. prednisone and methylprednisolone; interferons such as interferon- $\alpha$  (IFN- $\alpha$ ), IFN- $\beta$ , IFN- $\gamma$ , and other potential modulators such as e.g. interleukins (IL-1 - IL7).




FIG. 1




FIG. 2




FIG. 3




FIG. 4






FIG. 5

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/08004

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/439 A61K31/5513 A61K31/498 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S. BEN-ELIYAHU: "The NMDA receptor antagonist MK-801 blocks nonopioid stress induced analgesia and decreases tumor metastasis in the rat." PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, vol. 36, 1993, pages 293-298, XP002106887 the whole document	1-36
X	N. SEILER: "Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents." INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 30, no. 3, March 1998 (1998-03), pages 393-406, XP002089917 the whole document	1-36
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 February 2000

Date of mailing of the international search report

14/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Orviz Diaz, P

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/08004

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	K. IGARASHI: "Antagonist properties of polyamines and bis(ethyl)polyamines at N-methyl-D-aspartate receptors." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 272, no. 3, 1995, pages 1101-1109, XP002106888 the whole document	1-36
X	I. CHAUDIEU: "D-Aspartic Beta Hydroxymate (DAH), an Antitumoral Drug, Acts on N-Methyl-D-Aspartate Receptors in Rat Brain." J. NEUROCHEM., vol. 61, no. suppl, 1993, page S255 XP002106889 abstract	1-36
X	K. YAMADA: " Clinical and experimental studies on the antileukemic action of L-asparaginase" COLLOQ. INT. CENT. NAT. RECH. SCI., no. 197, 1971, pages 311-322, XP002106890 the whole document	1-36
X	US 4 885 171 A (SURENDRA SEHGAL N ET AL) 5 December 1989 (1989-12-05) the whole document	1-37
A	EP 0 778 023 A (AMERICAN HOME PROD) 11 June 1997 (1997-06-11) the whole document	1-37
X	EP 0 432 994 A (OLNEY JOHN WILLIAM) 19 June 1991 (1991-06-19) the whole document	36, 37

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/EP 99/ 08004

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

In view of the extremely large number of compounds mentioned in the claims, many of them characterised only by a generic structural definition, a complete search is not possible. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found for only a very small proportion of the compounds claimed. Consequently, the search had to be limited to the general inventive idea (use of glutamate antagonists for the manufacture of a medicament for treating cancer) and to the specific compounds used in the pharmacological examples.

Since the use of some of these compounds (MK 801, polyamines, rapamycin) for treating cancer is already known, the use of each of the compounds claimed would represent a separate invention. However, an objection of lack of unity has not been raised, because the documents cited in the Search Report, which were retrieved during the restricted search described in the previous paragraph, already cover the general inventive idea and some of the compounds used in the pharmacological examples, like MK 801 (see Proc. West. Pharmacol. Soc. 36:293-298, 1993).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4885171 A	05-12-1989	US 5206018 A	27-04-1993
		US 5066493 A	19-11-1991
		BE 877700 A	14-01-1980
		JP 55073616 A	03-06-1980
		ZA 7905449 A	26-11-1980
EP 0778023 A	11-06-1997	AU 700653 B	14-01-1999
		AU 7417896 A	12-06-1997
		BR 9605895 A	18-08-1998
		CA 2192298 A	08-06-1997
		CN 1159915 A	24-09-1997
		CZ 9800064 A	17-06-1998
		CZ 9603544 A	18-03-1998
		HU 9603370 A	28-05-1997
		IL 119778 A	14-07-1999
		JP 9183727 A	15-07-1997
		NO 965238 A	09-06-1997
		SK 154796 A	10-09-1997
EP 0432994 A	19-06-1991	US 5039528 A	13-08-1991